Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

21. Juli 2026 07:00 ET | Quelle: Agios Pharmaceuticals, Inc.

Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease

Agios provides update on Phase 2 trial of tebapivat in sickle cell disease
07. Juli 2026 07:00 ET | Quelle: Agios Pharmaceuticals, Inc.

U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease

Agios announces that the FDA has accepted its sNDA for mitapivat in sickle cell disease with a Priority Review
13. Juni 2026 09:00 ET | Quelle: Agios Pharmaceuticals, Inc.

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease

Agios showcases RISE UP Phase 3 results at EHA 2026 Plenary Session reinforcing strong anti-hemolytic profile of mitapivat in sickle cell disease
12. Mai 2026 09:31 ET | Quelle: Agios Pharmaceuticals, Inc.

Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease

Agios announces the submission of its sNDA to the FDA for the U.S. accelerated approval of mitapivat in sickle cell disease
12. Mai 2026 09:30 ET | Quelle: Agios Pharmaceuticals, Inc.

Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias

Agios announces new data on mitapivat will be featured in oral and poster presentations at EHA 2026 in Stockholm, Sweden, June 11-14, 2026
29. April 2026 06:30 ET | Quelle: Agios Pharmaceuticals, Inc.

Agios Reports First Quarter 2026 Financial Results and Provides Business Update

Agios announces first quarter 2026 financial results and provides business update.
22. April 2026 19:54 ET | Quelle: Exicure, Inc.

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

Exicure enters co-development agreement with Adbiotech to advance Burixafor (GPC-100) combination therapies across multiple indications.
20. April 2026 05:19 ET | Quelle: Novo Nordisk A/S

Novo Nordisk: Etavopivat is the first in a new class of drugs to meet both co-primary endpoints in the phase 3 HIBISCUS trial, substantially reducing vaso-occlusive crisis events and improving haemoglobin response in sickle cell disease

Etavopivat showed a 27% reduction in vaso-occlusive crisis events and ~4-month delay to first vaso-occlusive crisis event on top of standard of care1Haemoglobin response was superior with...
31. März 2026 07:00 ET | Quelle: Agios Pharmaceuticals, Inc.

Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA

Agios announces it will pursue U.S. accelerated approval for mitapivat in sickle cell disease
12. Februar 2026 06:30 ET | Quelle: Agios Pharmaceuticals, Inc.

Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Agios (Nasdaq: AGIO) announces financial results and updates for the fourth quarter and year ended December 31, 2025.

Nächste Seite